This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Actinium Pharmaceuticals To Present At EMIT Targeted Radiotherapy Conference









NEW YORK, Jan. 28, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, (OTC BB: CTVN), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, reported today that the program of the EMIT: Targeted Radiotherapy conference will feature three presentations devoted to Actinium Pharmaceuticals' clinical programs and technology platform.  These presentations will address broadening use of radiolabeled monoclonal antibodies for Hematopoietic Stem Cell Transplantation (HSCT) preparation in various indications; rationale for and prospects of a pivotal study of Iomab-B in relapsed and refractory acute myeloid leukemia (AML) patients; and successfully combining Actimab-A and low dose chemotherapy in front line treatment of older AML patients.

"These presentations demonstrate again both the progress we are making and the interest our product candidates and platforms elicit in the clinic for AML patients in particular," said Jack Talley, president and chief executive officer of Actinium.  "We intend to intensify our clinical programs this year and look forward to announcing additional milestones." 

The first Actinium program related presentation at this year's EMIT conference entitled "Radioimmunotherapy for Hematopoietic Cell Transplantation of Leukemia and Lymphoma: Emerging Therapy and Future Approaches" will focus on the expanding use in clinical trials of the CD45 targeting monoclonal antibody BC8 labeled with various radioisotopes for optimal match to the cancer being treated in the context of HSCT.  The second presentation entitled "Laying the Foundation for Stem Cell Transplantation with RIT for Enhanced Therapeutic Benefit" will focus on the unmet medical need of treating relapsed and refractory AML patients.  The third presentation "Targeted Alpha Particle Immunotherapy for Acute Myeloid Leukemia" will highlight results of front line treatment of older newly diagnosed AML patients. 

The following are the dates and times of the above referenced presentations:

January 30, 2013, 9.00 am: "Radioimmunotherapy for Hematopoietic Cell Transplantation of Leukemia and Lymphoma: Emerging Therapy and Future Approaches", presenter: John Pagel, MD, Associate Member, Clinical Research Division, Fred Hutchinson Cancer Center

January 31, 2013, 1.30 pm: "Laying the Foundation for Stem Cell Transplantation with RIT for Enhanced Therapeutic Benefit", presenter: Dragan Cicic, MD, COO & CMO, Actinium Pharmaceuticals

January 31, 2013, 2.00 pm: "Targeted Alpha Particle Immunotherapy for Acute Myeloid Leukemia", Joseph Jurcic, MD, Chief, Leukemia Services, New York Presbyterian/ Columbia

The above referenced oral presentations will take place at the One Washington Circle Hotel, One Washington Circle, N.W. Washington, D.C. 20037.

About Actinium Pharmaceuticals

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs